JMT203 / CSPC Pharma - LARVOL DELTA

JMT203-001: A Study of JMT203 in Patients With Cancer Cachexia (clinicaltrials.gov) - P1/2 | N=307 | Recruiting | Sponsor: Shanghai JMT-Bio Inc. | Phase classification: P1 ➔ P1/2 | N=130 ➔ 307 | Trial completion date: May 2028 ➔ May 2029 | Trial primary completion date: May 2026 ➔ Aug 2027

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Cachexia • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Safety, tolerability, and efficacy of JMT203 in patients with cancer cachexia: First results from a first-in-human phase I study (ESMO 2025) - P1 | "Conclusions JMT203 exhibits a favorable safety profile and an early-onset, sustained and progressive BW gain in cancer cachexia. Dose expansion is ongoing to optimize dosing and characterize biomarkers to inform the cohort-expansion (phase Ib) design."

Clinical • First-in-human • P1 data • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • GDF15

JMT203 (ANTI-GFRAL MONOCLONAL ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (HKEXnews) - "The board of directors...of CSPC Pharmaceutical Group Limited (the 'Company', together with its subsidiaries, the 'Group') is pleased to announce that the antibody drug JMT203 (the 'Product') independently developed by Shanghai JMT-BIO Technology Co., Ltd..., a subsidiary of the Company, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S."

IND • Cachexia • Metabolic Disorders

A Study of JMT203 in Patients With Cancer Cachexia (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P1 trial • Cachexia • Colorectal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

CHINA’S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (Irasia) - "The board of directors (the 'Board') of CSPC Pharmaceutical Group Limited...is pleased to announce that the antibody drug JMT203 (the 'Product') independently developed by Shanghai JMT-Bio Technology Co., Ltd...a subsidiary of the Company, has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China...The Product is a Class 1 innovative drug independently developed by the Group for the treatment of cancer cachexia....The preclinical studies have demonstrated that the product has good safety profile, and is able to significantly inhibit weight loss, increase non-fasting blood glucose and improve the forepaw grip strength of cachexia mouse, thereby relieving the cachexia symptoms and improving the tumor-bearing survival rate of cachexia mouse, and significantly increase the treatment tolerance and extend survival in combination with anti-tumor therapies."

New trial • Preclinical • Cachexia